A compound of formula (I) wherein $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^7$, $R^8$, $R^9$ and $Ar$ are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>GE</td>
<td>Georgia</td>
<td>MX</td>
<td>Mexico</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GN</td>
<td>Guinea</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GR</td>
<td>Greece</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>HU</td>
<td>Hungary</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>IE</td>
<td>Ireland</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>IT</td>
<td>Italy</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>JP</td>
<td>Japan</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>KE</td>
<td>Kenya</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>KP</td>
<td>Democratic People’s Republic of Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KR</td>
<td>Republic of Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d’Ivoire</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SG</td>
<td>Singapore</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>LR</td>
<td>Liberia</td>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
<td>LT</td>
<td>Lithuania</td>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LU</td>
<td>Luxembourg</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LV</td>
<td>Latvia</td>
<td>SZ</td>
<td>Swaziland</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MC</td>
<td>Monaco</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td>MD</td>
<td>Republic of Moldova</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>MG</td>
<td>Madagascar</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td>ML</td>
<td>Mali</td>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
<td>MN</td>
<td>Mongolia</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
<td>MR</td>
<td>Mauritania</td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>UG</td>
<td>Uganda</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
</tbody>
</table>
ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS

Background of the Invention

The present invention relates to arylsulfonfyl hydroxamic acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor (hereinafter also referred to as TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.

This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to the pharmaceutical compositions useful therefor.

There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalloproteases. Matrix-degrading metalloproteinases, such as gelatinase, stromelysin and collagenase, are involved in tissue matrix degradation (e.g. collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. corneal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Paget's disease and osteoporosis), tumor metastasis or invasion, as well as HIV-infection (J. Leuk. Biol., 52 (2): 244-248, 1992).

Tumor necrosis factor is recognized to be involved in many infectious and autoimmune diseases (W. Friers, FEBS Letters, 1991, 285, 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al., Clinical Immunology and Immunopathology, 1992, 62 S11).
Summary of the Invention

The present invention relates to a compound of the formula

or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

X is carbon, oxygen or sulfur;

Y is carbon, oxygen, sulfur, sulfoxide, sulfone or nitrogen;

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are selected from the group consisting of hydrogen, (C₁₋C₆)alkyl optionally substituted by (C₁₋C₆)alkylamino, (C₁₋C₆)alkythio, (C₁₋C₆)alkoxy, trifluoromethyl, (C₅₋C₁₀)aryl, (C₅₋C₆)heteroaryl, (C₅₋C₁₀)arylamino, (C₅₋C₁₀)arythio, (C₅₋C₁₀)aryloxy, (C₅₋C₆)heteroarylamino, (C₅₋C₆)heteroarythio, (C₅₋C₆)heteroaryloxy, (C₅₋C₁₀)aryl(C₅₋C₁₀)aryl, (C₃₋C₆)cycloalkyl, hydroxy(C₁₋C₆)alkyl, (C₁₋C₆)alkyl(hydroxymethylene), Piperazinyl,(C₅₋C₁₀)aryl(C₁₋C₆)alkoxy,(C₅₋C₆)heteroaryl(C₁₋C₆)alkoxy,(C₁₋C₆)acetylamino,(C₁₋C₆)acetyloxy,(C₁₋C₆)alkylsulfanyl, (C₁₋C₆)alkylsulfinyl, (C₁₋C₆)alkylsulfonyl, (C₅₋C₁₀)aryl(sulfonyl), amino, (C₁₋C₆)alkylamino or ((C₁₋C₆)alkylamino)₂; (C₂₋C₆)alkenyl, (C₅₋C₁₀)aryl(C₂₋C₆)alkenyl, (C₅₋C₆)heteroaryl(C₂₋C₆)alkenyl, (C₂₋C₆)alkynyl, (C₅₋C₁₀)aryl(C₂₋C₆)alkynyl, (C₅₋C₆)heteroaryl(C₂₋C₆)alkynyl, (C₁₋C₆)alkylamino, (C₁₋C₆)alkythio, (C₁₋C₆)alkoxy, trifluoromethyl, (C₁₋C₆)alkyl(difluoromethylene), (C₁₋C₆)alkyl(difluoromethylene)(C₁₋C₆)alkyl, (C₅₋C₁₀)aryl, (C₅₋C₆)heteroaryl, (C₅₋C₁₀)arylamino, (C₅₋C₁₀)arythio, (C₅₋C₆)heteroarylamino, (C₅₋C₆)heteroaryloxy, (C₅₋C₆)cycloalkyl, (C₁₋C₆)alkyl(hydroxymethylene), piperidyl, (C₁₋C₆)alkyl(piperidyl, (C₁₋C₆)acetylamino, (C₁₋
C₉acylthio, (C₁₋C₉)acloxy, R¹₃(C₁₋C₉)alhy wherein R¹₃ is (C₁₋C₉)acylpiperazino, (C₉₋C₁₀)arylpirazerino, (C₉₋C₉)heteroarylpirazerino, (C₁₋C₉)alkylpirazerino, (C₉₋C₉)alkylpirazerino, (C₉₋C₉)heteroaryl(C₁₋C₉)alkylpirazerino, morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl, (C₁₋C₉)alkylpiperidyl, (C₉₋C₉)heteroaryl(piperidyl)(C₁₋C₉)alkylpiperidyl(C₁₋C₉)alkyl, (C₉₋C₉)heteroaryl(piperidyl)(C₁₋C₉)alkylpiperidyl(C₁₋C₉)alkyl, or a group of the formula

```
0
Z

(CH₂)ₙ
```

wherein n is 0 to 6;

Z is hydroxy, (C₁₋C₉)alkoxy or NR₁⁴R₁⁵ wherein R₁⁴ and R₁⁵ are each independently selected from the group consisting of hydrogen, (C₁₋C₉)alkyl optionally substituted by (C₁₋C₉)alkylpiperidyl, (C₉₋C₉)arylpirazerino, (C₉₋C₉)heteroarylpirazerino, (C₉₋C₉)aryl, (C₉₋C₉)heteroaryl, (C₉₋C₉)aryl(C₉₋C₉)aryl or (C₉₋C₉)cycloalkyl; piperidyl, (C₁₋C₉)alkylpiperidyl, (C₉₋C₉)arylpirazerino, (C₉₋C₉)heteroarylpirazerino, (C₁₋C₉)acylpiperidyl, (C₉₋C₉)aryl, (C₉₋C₉)heteroaryl, (C₉₋C₉)aryl(C₉₋C₉)aryl, (C₉₋C₉)cycloalkyl, R¹⁶(C₂₋C₉)alkyl, (C₁₋C₉)alkyl(CHR¹₅)(C₁₋C₉)alkyl wherein R¹₅ is hydroxy, (C₁₋C₉)acloxy, (C₁₋C₉)alkoxy, piperazino, (C₁₋C₉)acylamino, (C₁₋C₉)alkythio, (C₉₋C₉)arythio, (C₁₋C₉)alkylsulfonyl, (C₉₋C₉)aryl, (C₁₋C₉)alkylsulfoxyl, (C₉₋C₉)aryl, (C₁₋C₉)alkylamino, (C₁₋C₉)acylpiperazino, (C₁₋C₉)acylpiperidino, (C₁₋C₉)arylpiperidino, (C₁₋C₉)arylpirazerino, morpholino, thiomorpholino, piperidino or pyrrolidino; R¹⁷(C₁₋C₉)alkyl, (C₁₋C₉)alkyl(CHR¹₅)(C₁₋C₉)alkyl wherein R¹₇ is piperidyl or (C₁₋C₉)alkylpiperidyl; and CH(R¹₈)COR¹₉ wherein R¹₈ is hydrogen, (C₁₋C₉)aryl, (C₉₋C₉)arylalkyl(C₁₋C₉)alkyl, (C₉₋C₉)heteroaryl(C₁₋C₉)alkyl, (C₁₋C₉)alkylthio(C₁₋C₉)alkyl, (C₉₋C₉)arylthio(C₁₋C₉)alkyl, (C₉₋C₉)alkylsulfanyl(C₁₋C₉)alkyl, (C₁₋C₉)alkylsulfanyl(C₁₋C₉)alkyl, (C₉₋C₉)arylsulfanyl(C₁₋C₉)alkyl, (C₁₋C₉)alkylsulfanyl(C₁₋C₉)alkyl, hydroxy(C₁₋C₉)alkyl, amino(C₁₋C₉)alkyl, (C₁₋C₉)alkylamino(C₁₋C₉)alkyl, (C₁₋C₉)alkylamino(C₁₋C₉)alkyl, R²₀R²¹NCO(C₁₋C₉)alkyl or R²₀R²¹OCO(C₁₋C₉)alkyl wherein R²₀ and R²¹ are each independently selected from the group consisting of hydrogen, (C₁₋
C_{10}alkyl, (C_2-C_{10})aryl,(C_1-C_9)alkyl and (C_9-C_{10})heteroaryl(C_1-C_9)alkyl; and R^{19} is R^{22}O or R^{22}R^{23}N wherein R^{22} and R^{23} are each independently selected from the group consisting of hydrogen, (C_1-C_9)alkyl, (C_9-C_{10})aryl,(C_1-C_9)alkyl and (C_9-C_{10})heteroaryl(C_1-C_9)alkyl; or R^{14} and R^{15}, or R^{20} and R^{21}, or R^{22} and R^{23} may be taken together to form an azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, (C_1-C_9)acylpiperazinyl, (C_1-C_9)alkylpiperazinyl, (C_9-C_{10})aryllicpiperazinyl, (C_9-C_{10})heteroarylpiperazinyl or a bridged diazabicycloalkyl ring selected from the group consisting of

\[ \text{Diagram a, b, c, d, e} \]

wherein \( r = 1, 2 \) or 3;

m is 1 or 2;

p is 0 or 1; and

Q is hydrogen, (C_1-C_3)alkyl, (C_1-C_9)acetyl or (C_1-C_9)alkoxy carbamoyl;
-5-

or R¹ and R², or R³ and R⁴, or R⁵ and R⁶ may be taken together to form a carbonyl;

or R¹ and R², or R³ and R⁴, or R⁵ and R⁶, or R⁷ and R⁸ may be taken together to form a (C₂⁻C₆)cycloalkyl, oxacyclohexyl, thiacyclohexyl, indanyl or tetralinyl ring or a group of the formula

\[
\begin{array}{c}
\text{R}^{24} \\
\end{array}
\]

wherein R²⁴ is hydrogen, (C₁⁻C₆)acyl, (C₁⁻C₆)alkyl, (C₆⁻C₁₀)aryl(C₁⁻C₆)alkyl, (C₆⁻C₆)heteroaryl(C₁⁻C₆)alkyl or (C₁⁻C₆)alkylsulfonyl; and

Ar is (C₆⁻C₁₀)aryl or (C₆⁻C₆)heteroaryl, each of which may be optionally substituted by (C₁⁻C₆)alkyl, one or two (C₁⁻C₆)alkoxy, (C₆⁻C₁₀)aryloxy or (C₆⁻C₆)heteroaryloxy;

with the proviso that R⁷ is other than hydrogen only when R⁸ is other than hydrogen;

with the proviso that R⁹ is other than hydrogen only when R⁸ is other than hydrogen;

with the proviso that R³ is other than hydrogen only when R⁴ is other than hydrogen;

with the proviso that R² is other than hydrogen only when R¹ is other than hydrogen;

with the proviso that when R¹, R² and R⁸ are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6-positions;

with the proviso that when X is nitrogen, R¹ is not present;

with the proviso that when X is oxygen, sulfur, sulfoxide, sulfone or nitrogen and when one or more of the group consisting of R¹, R², R⁵ and R⁸, is a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 4- or 6-positions;

with the proviso that when Y is oxygen, sulfur, sulfoxide, sulfone or nitrogen and when one or more of the group consisting of R³, R⁴, R⁷ and R⁸, are independently a
substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 3- or 5- positions;

with the proviso that when X is oxygen, sulfur, sulfoxide or sulfone, R³ and R⁴ are not present;

5 with the proviso that when Y is nitrogen, R⁴ is not present;

with the proviso that when Y is oxygen, sulfur, sulfoxide or sulfone, R⁵ and R⁶ are not present;

with the proviso that when Y is nitrogen, R⁶ is not present;

with the proviso that when the broken line represents a double bond, R⁴ and R⁶ are not present;

10 with the proviso that when R³ and R⁶ are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y;

with the proviso that when either the X or Y position is oxygen, sulfur, sulfoxide, sulfone or nitrogen, the other of X or Y is carbon;

15 with the proviso that when X or Y is defined by a heteroatom, the broken line does not represent a double bond;

with the proviso that when R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are all defined by hydrogen or (C₁-C₆)alkyl, either X or Y is oxygen, sulfur, sulfoxide, sulfone or 20 nitrogen, or the broken line represents a double bond.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is 25 defined above.

The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluoro, chloro, cyano, nitro, trifluoromethyl, (C₁-C₆)alkoxy, 30 (C₆-C₁₀)aryloxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.

The term "heteroaryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl,
tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoazolyl, thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents independently selected from the group consisting of fluoro, chloro, trifluoromethyl, (C₁-C₆)alkoxy, (C₅-C₁₀)aryloxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl.

The term "acyl", as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy, aryl, arylalkyl or arylalkyloxy and the terms "alkyl" or "aryl" are as defined above.

The term "acyloxy", as used herein, includes O-acyl groups wherein "acyl" is defined above.

The positions on the ring of formula I, as used herein, are defined as follows:

The preferred conformation of the compound of formula I includes hydroxamic acid axially disposed in the 2-position.

The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.

Preferred compounds of formula I include those wherein Y is oxygen, nitrogen or sulfur.

Other preferred compounds of formula I include those wherein Ar is 4-methoxyphenyl or 4-phenoxyphenyl.

Other preferred compounds of formula I include those wherein R² is (C₅-C₁₀)aryl, (C₅-C₆)heteroaryl, (C₅-C₁₀)aryl(C₁-C₆)alkyl, (C₅-C₆)heteroaryl(C₁-C₆)alkyl, carboxylic acid or carboxylic acid (C₁-C₆)alkyl.

Other preferred compounds of formula I include those wherein R², R³, R⁶, R⁷ and R⁸ are hydrogen.
More preferred compounds of formula I include those wherein \( Y \) is carbon, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is \((C_6-C_{10})\)arylalkynyl or \((C_6-C_9)\)heteroarylalkynyl.

More preferred compounds of formula I include those wherein \( Y \) is oxygen, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is \((C_6-C_{10})\)arylalkynyl or \((C_6-C_9)\)heteroarylalkynyl.

More preferred compounds of formula I include those wherein \( Y \) is carbon, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is carboxylic acid or carboxylic acid \((C_1-C_6)\)alkyl.

More preferred compounds of formula I include those wherein \( Y \) is oxygen, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is carboxylic acid or carboxylic acid \((C_1-C_6)\)alkyl.

More preferred compounds of formula I include those wherein \( Y \) is carbon, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is \((C_6-C_{10})\)arylalkynyl or \((C_6-C_9)\)heteroarylalkynyl.

More preferred compounds of formula I include those wherein \( Y \) is oxygen, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is \((C_6-C_{10})\)arylalkynyl or \((C_6-C_9)\)heteroarylalkynyl.

More preferred compounds of formula I include those wherein \( Y \) is carbon, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is carboxylic acid or carboxylic acid \((C_1-C_6)\)alkyl.

More preferred compounds of formula I include those wherein \( Y \) is oxygen, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is carboxylic acid or carboxylic acid \((C_1-C_6)\)alkyl.

More preferred compounds of formula I include those wherein \( Y \) is carbon, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is \((C_1-C_6)\)alkylamino.

More preferred compounds of formula I include those wherein \( Y \) is oxygen, \( Ar \) is 4-methoxyphenyl or 4-phenoxyphenyl and \( R^5 \) is \((C_1-C_6)\)alkylamino.

Specific preferred compounds of formula I include the following:

- \((2R,3S)-N\)-hydroxy-3-ethynyl-1-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide;
- \((2R,3S)-N\)-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(5-methoxythiophene-2-yl-ethynyl)-piperidine-2-carboxamide;
(2R,3R)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(3-pyridin-3-yl-prop-2-ynyl)-piperidine-2-carboxamide;
(2S,3R)-N-hydroxy-4-(4-methoxybenzenesulfonyl)-2-pyridine-3-yl-morpholine-3-carboxamide;
(2S,3R)-N-hydroxy-2-hydroxycarbamoyl-4-(4-methoxybenzenesulfonyl)-morpholine-3-carboxamide;
(2R,3R)-N-hydroxy-2-hydroxycarbamoyl-4-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide;
(2R,3S)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(4-phenylpyridine-2-yl)-piperidine-2-carboxamide;
(2S,3R)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-2-(4-phenylpyridine-2-yl)-morpholine-2-carboxamide;
(2R,3S)-N-hydroxy-3-(2-chloro-4-fluorophenyl)-1-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide; and
(2S,3R)-N-hydroxy-2-(2-chloro-4-fluorophenyl)-1-(4-methoxybenzenesulfonyl)-piperidine-3-carboxamide.

The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such treatments or inhibition and a pharmaceutically acceptable carrier.

The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the
production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in treating such a condition.
Detailed Description of the Invention

The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated \( R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, n \) and \( Ar \) in the reaction Schemes and the discussion that follow are defined as above.

Preparation 1

\[
\begin{align*}
&\text{XVI} \\
&\text{1} \\
&\text{VI}
\end{align*}
\]
Preparation 2

\[
\begin{align*}
R^9 & \quad \text{CO}_2 R^{25} \\
\text{NH}_2 & \\
\end{align*}
\]

XVIII

\[
\begin{align*}
\text{CHO} & \quad \text{CO}_2 R^{25} \\
R^1 & \quad \text{N} \quad R^9 \\
R^2 & \quad \text{SO}_2 \text{Ar} \\
\end{align*}
\]

XVII

\[
\begin{align*}
R^8 & \quad \text{OH} \quad \text{CO}_2 R^{25} \\
R^1 & \quad \text{N} \quad R^9 \\
R^2 & \quad \text{SO}_2 \text{Ar} \\
\end{align*}
\]

VI
Scheme 1

5

VI

R^8
\begin{array}{c}
\text{R}^5 \\
\text{R}^3 \\
\text{R}^1 \\
\text{N} \\
\text{R}^9 \\
\text{SO}_2\text{Ar}
\end{array}

\text{CO}_2\text{R}^{25}

1 \rightarrow

V

R^8
\begin{array}{c}
\text{R}^5 \\
\text{R}^3 \\
\text{R}^1 \\
\text{N} \\
\text{R}^9 \\
\text{SO}_2\text{Ar}
\end{array}

\text{O}

2

10

R^5
\begin{array}{c}
\text{R}^3 \\
\text{R}^1 \\
\text{N} \\
\text{R}^9 \\
\text{NH}_2\text{OH}
\end{array}

\text{SO}_2\text{Ar}

3

15

III

R^5
\begin{array}{c}
\text{R}^3 \\
\text{R}^1 \\
\text{N} \\
\text{R}^9 \\
\text{NH}_2\text{OH}
\end{array}

\text{SO}_2\text{Ar}

4

20

IV

R^5
\begin{array}{c}
\text{R}^3 \\
\text{R}^1 \\
\text{N} \\
\text{R}^9 \\
\text{O}
\end{array}

\text{SO}_2\text{Ar}

30

II

R^5
\begin{array}{c}
\text{R}^3 \\
\text{R}^1 \\
\text{N} \\
\text{R}^9 \\
\text{NH}_2\text{OH}
\end{array}

\text{SO}_2\text{Ar}
Scheme 2

\[ R^{26} \]

\[ \text{IX} \]

\[ \text{VIII} \]

\[ \text{VII} \]
Scheme 3

XII

XI

X

WO 96/33172

PCT/IB95/00279
Scheme 4

XXII → 1 → XXI → 2 → XX

5

10

15

20

25

30
Scheme 4 continued

XX

3

XIX

4

XIII
Scheme 5

\[
\begin{align*}
\text{XXVI} & \quad \text{1} \\
\text{XXV} & \quad \text{2} \\
\text{XXIV} & \\
\end{align*}
\]
Scheme 5 continued

XXIV

3

10

COOR

SO\textsubscript{2}Ar

XXIII

4

20

NH\textsubscript{2}

SO\textsubscript{2}Ar

XIV

25
In reaction 1 of Preparation 1, the compound of formula XVI is converted to the corresponding hydroxy ester compound of formula VI by first reacting XVI with an arylsulfonylhalide in the presence of triethylamine and an aprotic solvent, such as methylene chloride, tetrahydrofuran or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature. The compound so formed is further reacted with a compound of the formula

![formula]

wherein R²⁵ is carbobenzyloxy, (C₁₋₆)alkyl, benzyl, allyl or tert-butyl, in the presence of sodium hexamethyldisilazane and a tetrahydrofuran-dimethylformamide solvent mixture at a temperature between about -20°C to about 20°C, preferably about 0°C, to form the hydroxy ester compound of formula VI.

In reaction 1 of Preparation 2, the amine compound of formula XVIII, wherein R²⁵ is as defined above, is converted to the corresponding arylsulfonyl amine compound of formula XVII by (1) reacting XVIII with an arylsulfonylhalide in the presence of triethylamine and an aprotic solvent, such as methylene chloride, tetrahydrofuran, or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature, (2) reacting the compound so formed with a compound of the formula

![formula]

in the presence of sodium hexamethyldisilazane and a tetrahydrofuran-dimethylformamide solvent mixture at a temperature between about -20°C to about 20°C, preferably about 0°C, and (3) further reacting the compound so formed with ozone in a methylene chloride-methanol solution at a temperature between about -90°C to about -70°C, preferably about -78°C. The unstable ozonide compound so formed is then reacted with triphenylphosphine to form the arylsulfonyl amine compound formula XVII. In Reaction 2 of Preparation 2, the arylsulfonyl amine compound of formula XVII is converted to the corresponding hydroxy ester compound of formula VI by reacting XVII with a compound of the formula
wherein W is lithium, magnesium, copper or chromium.

In reaction 1 of Scheme 1, the compound of formula VI, wherein the \( R^{25} \) protecting group is carbobenzyloxy, \((C_1-C_6)\) alkyl, benzy1, allyl or tert-butyl, is converted to the corresponding morpholinone compound of formula V by lactonization and subsequent Claisen rearrangement of the compound of formula VI. The reaction is facilitated by the removal of the \( R^{25} \) protecting group from the compound of formula VI is carried out under conditions appropriate for that particular \( R^{25} \) protecting group in use. Such conditions include: (a) treatment with hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where \( R^{25} \) is carbobenzyloxy, (b) saponification where \( R^{25} \) is lower alkyl, (c) hydrogenolysis where \( R^{25} \) is benzy1, (d) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid, where \( R^{25} \) is tert-butyl, or (e) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where \( R^{25} \) is allyl.

In reaction 2 of Scheme 1, the morpholinone compound of formula V is converted to the carboxylic acid compound of formula IV by reacting V with lithium hexamethyldisilazane in an aprotic solvent, such as tetrahydrofuran, at a temperature between about -90°C to about -70°C, preferably about -78°C. Trimethylsilyl chloride is then added to the reaction mixture and the solvent, tetrahydrofuran, is removed in vacuo and replaced with toluene. The resulting reaction mixture is heated to a temperature between about 100°C to about 120°C, preferably about 110°C, and treated with hydrochloric acid to form the carboxylic acid compound of formula IV.

In reaction 3 of Scheme 1, the carboxylic acid compound of formula IV is converted to the corresponding hydroxamic acid compound of formula III by treating IV with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenztriazole in a polar solvent, such as dimethylformamide, followed by the addition of hydroxylamine to the reaction mixture after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxylamine is preferably generated in situ from a salt form, such as hydroxylamine hydrochloride, in the presence of a base, such as N-methylmorpholine. Alternatively, a protected derivative of hydroxylamine or its salt
form, where the hydroxyl group is protected as a tert-butyl, benzyl or allyl ether, may be used in the presence of (benzotriazol-1-yl oxy)tris(dimethylamino) phosphonium hexafluorophosphate and a base, such as N-methylmorpholine. Removal of the hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride. N,O-bis(4-methoxybenzyl)hydroxylamine may also be used as the protected hydroxylamine derivative where deprotection is achieved using a mixture of methanesulfonic acid and trifluoroacetic acid.

In reaction 4 of Scheme 1, the hydroxamic acid compound of formula III is converted, if desired, to the corresponding piperidine compound of formula II by treating III with hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon.

In reaction 1 of Scheme 2, the arylsulfonylpiperazine compound of formula IX, wherein R²⁸ is carbobenzyloxy, benzyl or carbotertbutyloxy, is converted to the compound of formula VIII by reacting IX with a protected derivative of hydroxylamine of the formula

\[ R^{27} \text{ONH}_2 \cdot \text{HCl} \]

wherein R²⁷ is tertbutyl, benzyl or allyl, in the presence of dicyclohexylcarbodiimide, dimethylaminopyridine and an aprotic solvent, such as methylene chloride. The R²⁸ protecting group is chosen such that it may be selectively removed in the presence of an without loss of the R²⁷ protecting group, therefore, R²⁸ cannot be the same as R²⁷. Removal of the R²⁸ protecting group from the compound of formula IX is carried out under conditions appropriate for that particular R²⁸ protecting group in use. Such conditions include; (a) treatment with a hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where R²⁸ is carbobenzyloxy, (b) hydrogenolysis where R²⁸ is benzylo or (c) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid where R²⁸ is carbotertbutyloxy.

In reaction 2 of Scheme 2, the compound of formula VIII is converted to the corresponding hydroxamic acid compound of formula VII, wherein R⁵ is hydrogen or (C₁-C₆)alkyl, by reacting, if desired, VIII with an alkylhalide when R⁵ is (C₁-C₆)alkyl. Subsequent removal of the R²⁷ hydroxylamine protecting group is carried out by
hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride.

In reaction 1 of Scheme 3, the arylsulfonfylamine compound of formula XII, wherein R²⁵ is as defined above, is converted to the corresponding piperazine compound of formula XI by reacting XII with a carbodiimide and a base, such as triethylamine. The compound of formula XI is further reacted to give the hydroxamic acid compound of formula X according to the procedure described above in reaction 3 of Scheme 1.

In reaction 1 of Scheme 4, removal of the R²⁸ protecting group and subsequent reductive amination of the compound of formula XXII, wherein Y is oxygen, sulfur or carbon, to give the corresponding imine compound of formula XXI is carried out under conditions appropriate for that particular R²⁸ protecting group in use. Such conditions include those used above for removal of the R²⁵ protecting group in reaction 1 of Scheme 2.

In reaction 2 of Scheme 4, the imine compound of formula XXI is converted to the corresponding piperidine compound of formula XX by reacting XXI with a nucleophile of the formula R²⁷M wherein M is lithium, magnesium halide or cerium halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, at a temperature between about -78°C to about 0°C, preferably about -70°C.

In reaction 3 of Scheme 4, the sulfonation of the piperidine compound of formula XX to give the corresponding arylsulfonfylpiperidine compound of formula XIX is carried out by reacting XX with an arylsulfonfylhalide in the presence of triethylamine and an aprotic solvent, such as metherone chloride, tetrahydrofuran or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature.

In reaction 4 of Scheme 4, the arylsulfonfylpiperidine compound of formula XIX is converted to the hydroxamic acid compound of formula XIX according to the procedure described above in reaction 3 of Scheme 1.

In reaction 1 of Scheme 5, the compound of formula XXVI, wherein the R²⁹ and R³¹ protecting groups are each independently selected from the group consisting of carbobenzyloxy, benzyl and carbotertbutyloxy and R³⁰ is carbobenzyloxy, (C₁₋₅)alkyl,
benzyl, allyl or tert-butyl, is converted to the corresponding imine compound of formula XXV by the removal of the R²₉ protecting group and subsequent reductive amination of the compound of formula XXVI. The R²₉ protecting group is chosen such that it may be selectively removed in the presence of and without loss of the R³¹ protecting group. 

Removal of the R²₉ protecting group from the compound of formula XXVI is carried out under conditions appropriate for that particular R²₉ protecting group in use which will not affect the R³¹ protecting group. Such conditions include; (a) treatment with hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where R²₉ is carbobenzylxoy and R³¹ is tert-butyl, (b) saponification where R²₉ is (C₁₋C₆)alkyl and R³¹ is tert-butyl, (c) hydrogenolysis where R²₉ is benzyl and R³¹ is (C₁₋C₆) alkyl or tert-butyl, (d) treatment with a strong acid such as trifluoroacetic acid or hydrochloric acid where R²₉ is tert-butyl and R³¹ is (C₁₋C₆)alkyl, benzyl or allyl, or (e) treatment with tributytinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R²₉ is allyl and R³¹ is (C₁₋C₆)alkyl, benzyl or tert-butyl. The R³₀ protective group may be selected such that it is removed in the same reaction step as the R²₉ protecting group.

In reaction 2 of Scheme 5, the imine compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with a nucleophile of the formula R₃M wherein M is lithium, magnesium halide or calcium halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, at a temperature between about -78°C to about 0°C, preferably about -70°C.

In reaction 3 of Scheme 5, the sulfonation of the piperidine compound of formula XXIV to give the corresponding arylsulfonylpiperidine compound of formula III is carried out according to the procedure described above in reaction 3 of Scheme 4.

In reaction 4 of Scheme 5, the arylsulfonylpiperidine compound of formula XXIII is converted to the hydroxamic acid compound of formula XIV by (1) removing the R³₀, if needed, and R³¹ protecting groups from XXIII followed by (2) reacting XXIII according to the procedure described above in reaction 3 of Scheme 1. Removal of the R³₀ and R³¹ protecting groups from the compound of formula XXIII is carried out under conditions appropriate for that particular R³₀ and R³¹ protecting group in use. Such conditions include those used above for removal of the R²₅ protecting group in reaction 1 of Scheme 1.
Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methylammonium salts.

Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.

The ability of the compounds of formula I or their pharmaceutically acceptable salts (hereinafter also referred to as the compounds of the present invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following in vitro assay tests.

**Biological Assay**

**Inhibition of Human Collagenase (MMP-1)**

Human recombinant collagenase is activated with trypsin using the following ratio: 10 µg trypsin per 100 µg of collagenase. The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 µg/10 µg trypsin) of soybean trypsin inhibitor is added.

10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme:

10 mM ———> 120 µM ———> 12 µM ———> 1.2 µM ———> 0.12 µM

Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.

Collagenase is diluted to 400 ng/ml and 25 µl is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/ml.

Substrate (DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 µM in assay buffer. The assay is
initiated by the addition of 50 µl substrate per well of the microfluor plate to give a final concentration of 10 µM.

Fluorescence readings (360 nM excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours.

Fluorescence vs time is then plotted for both the blank and collagenase containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC₅₀ values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100). IC₅₀'s are determined from the concentration of inhibitor that gives a signal that is 50% of the control.

If IC₅₀'s are reported to be <0.03 µM then the inhibitors are assayed at concentrations of 0.3 µM, 0.03 µM, 0.03 µM and 0.003 µM.

**Inhibition of Gelatinase (MMP-2)**

Inhibition of gelatinase activity is assayed using the Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂ substrate (10 µM) under the same conditions as inhibition of human collagenase (MMP-1).

72kD gelatinase is activated with 1 mM APMA (p-aminophenyl mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give final concentrations in the assay of 30 µM, 3 µM, 0.3 µM and 0.03 µM. Each concentration is done in triplicate.

Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minute intervals for 4 hours.

IC₅₀'s are determined as per inhibition of human collagenase (MMP-1). If IC₅₀'s are reported to be less than 0.03 µM, then the inhibitors are assayed at final concentrations of 0.3 µM, 0.03 µM, 0.003 µM and 0.003 µM.
Inhibition of Stromelysin Activity (MMP-3)


Human recombinant prostromelysin is activated with trypsin using a ratio of 1 μl of a 10 mg/ml trypsin stock per 26 μg of stromelysin. The trypsin and stromelysin are incubated at 37°C for 15 minutes followed by 10 μl of 10 mg/ml soybean trypsin inhibitor for 10 minutes at 37°C for 10 minutes at 37°C to quench trypsin activity.

Assays are conducted in a total volume of 250 μl of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microtiter plates. Activated stromelysin is diluted in assay buffer to 25 μg/ml. Ellman's reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 μl per well yielding at 1 mM final concentration.

10 mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 μL to the appropriate wells yields final concentrations of 3 μM, 0.3 μM, 0.003 μM, and 0.0003 μM. All conditions are completed in triplicate.

A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 μl to each well to give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman's reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader.

IC\textsubscript{50} values were determined in the same manner as for collagenase.

Inhibition of MMP-13

Human recombinant MMP-13 is activated with 2 mM APMA (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5 mM calcium chloride, 20 μM zinc chloride, 0.02% brij). Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.
10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 μM, 3μM, 0.3 μM, and 0.03 μM.

Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is prepared as for inhibition of human collagenase (MMP-1) and 50 μl is added to each well to give a final assay concentration of 10 μM. Fluorescence readings (360 nM excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour.

Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.

IC₅₀'s are determined as per inhibition of human collagenase (MMP-1). If IC₅₀'s are reported to be less than 0.03 μM, inhibitors are then assayed at final concentrations of 0.3 μM, 0.03 μM, 0.003 μM and 0.0003 μM.

Inhibition of TNF Production

The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following in vitro assay:

Human mononuclear cells were isolated from anti-coagulated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2 x 10⁶ /ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations.

180μl of the cell suspension was aliquoted into flat bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 200μl. All conditions were performed in triplicate. After a four hour incubation at 37°C in an humidified CO₂ incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supernatants removed and assayed for TNFα using the R&D ELISA Kit.

For administration to humans for the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF), a variety of conventional routes may be
used including orally, parenterally and topically. In general, the active compound will be administered orally or parenterally at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

The compounds of the present invention can be administered in a wide variety of different dosage forms, in general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these
solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

Additionally, it is possible to administer the compounds of the present invention topically, e.g., when treating inflammatory conditions of the skin and this may be done by way of creams, jellies, gels, pastes, and ointments, in accordance with standard pharmaceutical practice.

The present invention is illustrated by the following examples, but it is not limited to the details thereof.

**EXAMPLE 1**

(±)-(2R*,3R*)-(N-hydroxy)-1-(4-methoxy-benzene sulfonyl)-3-methyl-1,2,3,6-tetrahydropyridine-2-carboxamide.

(a) To a solution of (E)-1-amo-3-pentent-2-ol (2.0 grams, 10.0 mmol) in methylene chloride (50 ml) is added triethylamine (160 µL, 11.0 mmol) followed by 4-methoxybenzenesulfonyl chloride (2.07 grams, 10.0 mmol). The mixture is stirred at room temperature for 12 hours and diluted with ethyl acetate. The mixture is washed with water, 10% citric acid, dried (sodium sulfate), filtered and concentrated. The crude product is purified by silica gel chromatography (elution with 2:1 ethyl acetate-hexanes) to provide (N-(2-hydroxy-pent-3-enyl)-4-methoxybenzenesulfonylamide.

(b) To a solution of (±)-(E)-N-(2-hydroxy-pent-3-enyl)-4-methoxybenzenesulfonyamide (1.2 grams, 4.42 mmol) in tetrahydrofuran-dimethylformamide (10 mL, ca. 3:1) at 0°C is added sodium bis(trimethylsilyl)amide (4.9 mL, 1.0 M solution in tetrahydrofuran). After 10 minutes, t-butyldibromomacetate (786 mL, 4.83 mmol) is added. The mixture is warmed to room temperature, stirred for 1 hour and quenched with saturated ammonium chloride solution. The mixture is extracted with ethyl acetate and the combined extracts are dried (sodium sulfate), filtered and concentrated. The crude product is purified by silica gel chromatography (elution with 1:1 ethyl acetate-hexanes) to provide [(2-hydroxy-pent-3-enyl)-(4-methoxybenzenesulfonyl)-amino]-acetic acid t-buty1 ester.

(c) To a solution of (±)-(E)-N-(2-hydroxy-pent-3-enyl)-4-methoxybenzenesulfonylamido-acyclic acid t-buty1 ester (900 mg, 2.43 mmol) in benzene (10 ml) is added trifluoroacetic acid (56 µL, 0.73 mmol). The solution is heated at 80°C for 3 hours, cooled to room temperature and concentrated to provide
(±)-(E)-4-(4-methoxybenzenesulfonyl)-6-propenylmorpholin-2-one which is used without further purification.

(d) To a solution of lithium bis(trimethylsilyl)amide (2.67 mmol, 1.0 M in tetrahydrofuran) in tetrahydrofuran (5.0 ml) at -78°C is added a solution of (±)-(E)-4-(4-methoxybenzenesulfonyl)-6-propenylmorpholine-2-one crude from the previous step. After 15 minutes, trimethylsilyl chloride (1.53 ml, 12.15 mmol) is added and the mixture warmed to room temperature. The solvent is removed (in vacuo) and replaced with toluene (10 ml). The resulting mixture is heated at 110°C for 3 hours, cooled to room temperature and treated with 1N hydrochloric acid solution. After stirring for 10 minutes, the mixture is extracted with ethyl acetate and the combined extracts are dried (sodium sulfate), filtered and concentrated. The crude product is purified by silica gel chromatography (elution with 2:1 ethyl acetate-hexanes with 1% acetic acid) to provide (±)-(2R*, 3R*)-1-(4-methoxy-benzenesulfonyl)-3-methyl-1,2,3,6-tetrahydropyridine-2-carboxylic acid.

(e) To a sodium of (±)-(2R *,3R *)-1-(4-methoxy-benzenesulfonyl)-3-methyl-1,2,3,6-tetrahydropyridine-2-carboxylic acid (100 mg, 0.36 mmol) in dimethylformamide (5 ml) is added hydroxybentiazole (53 mg, 0.39 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (75 mg, 0.39 mmol). After 1 hour, hydroxylamine hydrochloride (75 mg, 1.08 mmol) is added followed by triethylamine (150 µL, 1.08 mmol). After stirring overnight, the mixture is diluted with water and extracted with ethyl acetate. The combined extracts are dried, filtered and concentrated. The crude product is purified by silica gel chromatography (elution with 2:1 ethyl acetate-hexanes with 1% acetic acid) to provide (±)-(2R *,3R *)-(N-hydroxy)-1-(4-methoxy-benzenesulfonfyl)-3-methyl-1,2,3,6-tetrahydropyridine-2-carboxamide as a white solid.

Melting point 173°C (dec.). Mass spectrum (thermospray): m/z 326 (m-C(O)N(H)OH, 100%, (m, 7%), (m+H, 30%), (m+NH4, 10%). 1H NMR (CDCl3, 250 MHz, ppm): δ 7.72 (d, J = 8.9 Hz, 2H), 7.03 (d, J=8.9 Hz, 2H), 5.66 (dq, J=13.0, 2.7 Hz, 1H), 5.45 (dd, 13.0, 1.9 Hz), 4.37 (d, 7.0 Hz, 1H), 4.06-3.82 (m, 2H), 3.82 (s, 3H), 3.43-3.30 (m, 1H), 2.62-2.31 (m, 1H), 0.97 (d, 7.5 Hz, 3H).
EXAMPLE 2

N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-phenyl-1,2,3,6-
tetrahydropyridine-2-carboxamide

(a) To a solution of glycine t-buty l ester (5.0 grams, 29.82 mmol) in
methylene chloride (50 ml) is added triethylamine (6.65 ml, 62.63 mmol) followed by 4-
methoxybenzenesulfonyl chloride (29.82 mmol, 6.2 grams). The solution is stirred for
24 hours, diluted with water and extracted with ethyl acetate. The combined extracts
are dried (sodium sulfate), filtered and concentrated. The crude product is purified by
silica gel chromatography (elution with 6:1 hexane-ethyl acetate) to provide (4-
methoxybenzenesulfonylamino) acetic acid t-buty l ester.

(b) To a solution of (4-methoxybenzenesulfonylamino) acetic acid t-buty l
ester (3.0 grams, 10 mmol) in tetrahydrofuran-dimethylformamide (mL, ca. 3:1) at 0°C
is added sodium bis(trimethylsilyl)amide (10.0 mL, 1.0 M solution in tetrahydrofuran).
After 10 minutes, 4-bromo-2-methyl-2-butene (1.27 μL, 11.0 mmol) is added. The
mixture is warmed to room temperature, stirred for 1 hour and quenched with saturated
ammonium chloride solution. The mixture is extracted with ethyl acetate and the
combined extracts are dried (sodium sulfate), filtered and concentrated. The crude
product is purified by silica gel chromatography (elution with 1:1 ethyl acetate-hexanes)
to provide [(4-methoxybenzenesulfonyl)-(3-methyl-but-2-enyl)-amino]-acetic acid t-buty l
ester.

(c) Ozone is passed through a solution of [(4-methoxybenzenesulfonyl)-(3-
methyl-but-2-enyl)-amino]-acetic acid t-buty l ester (2.0 grams, 5.4 mmol) in methylene
chloride-methanol (50 mL, ca. 1:1) at -78°C until a blue color persisted.
Triphenylphosphine (4.24 grams, 16.2 mmol) is added and the resulting solution is
stirred at room temperature for 3 hours. Concentration provided the crude product
which is purified by silica gel chromatography (elution with 1:1 ethyl acetate-hexanes)
to provide [(4-methoxybenzenesulfonyl)-(2-oxo-ethyl)-amino]-acetic acid t-buty l ester.

(d) To a slurry of chromium (II) chloride (1.3 grams, 10.49 mmol) in
dimethylformamide (20 mL) is added a suspension of nickel (II) chloride (0.026 mmol, 
1 mg) in dimethylformamide (1 mL) followed by a mixture of (trans)-β-iodostyrene (1.20 
grams, 5.24 mmol) and [(4-methoxybenzenesulfonyl)-2-oxo-ethyl)-amino]acetic acid t-
buty l ester (900 mg, 2.62 mmol) in dimethylformamide (5 mL). The resulting solution is
stirred for three hours, diluted with water and extracted with ethyl acetate. The
combined extracts are washed with brine, dried (sodium sulfate), filtered and concentrated. The crude product is purified by silica gel chromatography (elution with 3:2 hexane-ethyl acetate) to provide (+)-(E)-[(2-hydroxy-4-phenyl-but-3-enyl)-(4-methoxybenzenesulphonyl)-amino]-acetic acid t-butyl ester.

5. (+)-(E)-[(2-hydroxy-4-phenyl-but-3-enyl)-(4-methoxybenzenesulphonyl)-amino]-acetic acid t-butyl ester is subjected to the conditions described in Example 1c. The crude product is recrystallized from chloroform to provide (+)-(E)-4-(4-methoxybenzenesulfonyl)-6-styryl-morpholin-2-one.

(f) (+)-(E)-4-(4-methoxybenzenesulfonfonyl)-6-styryl-morpholin-2-one is subjected to the conditions described in Example 1d. The crude product is purified by silica gel chromatography (elution with 2:1 hexane-ethyl acetate with 1% acetic acid) to provide (+)-(2R*-3R*)-1-(4-methoxybenzenesulfonyl)-3-phenyl-1,2,3,6-tetrahydropyridine-2-carboxylic acid.

(g) (+)-(2R*-3R*)-1-(4-methoxybenzenesulfonyl)-3-phenyl-1,2,3,6-tetrahydropyridine-2-carboxylic acid is subject to the conditions described in Example 1e. The crude product is purified by silica gel chromatography (elution with 1:1 hexane-ethyl acetate with 1% acetic acid) to provide N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-phenyl-1,2,3,6-tetrahydropyridine-2-carboxamide as a white solid. Melting point 151-154°C (dec.). Mass spectrum [PBMS w/C.I. (NH₃)]: m/z 388 (m+NH₄⁺, 100%). ¹H NMR (CD₂OD) δ 7.75 (d, J = 8.5 Hz, 2H), 7.38-7.12 (m, 5H), 7.04 (d, J = 8.5 Hz, 2H), 5.91 (d, J = 8.9 Hz, 1H), 5.28 (d, J = 9.9 Hz, 1H), 4.89 (s, H₅O), 4.57 (d, J = 6.8 Hz, 1H), 4.07 (ABq, JAB = 18.0 Hz, ∆ ν AB = 39.1 Hz, 2H), 3.85 (s, 3H), 3.39 (bs, CD₂OD).

EXAMPLE 3

(+)-(2R*-3R*)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-phenyl-piperidine-2-carboxamide

(a) To a solution of (+)-(2R*-3R*)-1-(4-methoxybenzenesulfonyl)-3-phenyl-1,2,3,6-tetrahydropyridine-2-carboxylic acid (65 mg, 0.17 mmol) (from Example 20), is added benzylhydroxylamine hydrochloride (32 mg, 0.20 mmol), dicyclohexylcarbodiimide (41 mg, 0.20 mmol) and dimethylaminopyridine (27 mg, 0.22 mmol). The resulting mixture is stirred overnight, diluted with ethyl acetate and filtered through Celite™ and evaporated. The crude product is purified by chromatography elution with 1:1 hexane-ethyl acetate to provide (+)-(2R*-3R*)-N-benzylxy-1-(4-methoxybenzenesulfonyl)-3-phenyl-1,2,3,6-tetrahydropyridine-2-carboxamide.
(b) To a solution of \((\pm)-(2R^*-3R^*)\)-N-benzylxoy-1-(4-methoxybenzenesulfonlyl)-3-phenyl-1,2,3,6-tetrahydropyridine-2-carboxamide (35 mg, 0.073 mmol) in ethanol (5 ml) is added 10% palladium on carbon (10 mg, 5 mol). The flask is evacuated and backfilled with hydrogen (repeated two times). The reaction mixture is then stirred for 1 hour at which time it is filtered through Celite\textsuperscript{TM} and concentrated. The product \((\pm)-2R^*-3R^*)\)-N-hydroxy-1-(4-methoxybenzenesulfonlyl)-3-phenylpiperidine-2-carboxamide was collected as a white solid. Melting point 163\textdegree C (dec). Mass spectrum [PBMS w/C.l. \((\text{NH}_3)\): m/z 390 (m+H\textsubscript{2}), (m+NH\textsubscript{4}). \textsuperscript{1}H NMR (CD\textsubscript{3}OD) \(\delta\) 7.73 (d, J = 8.9 Hz, 2H), 7.31-737 (m, 5H), 7.04 (d, 8.9 Hz, 2H0, 4.89 (s, H\textsubscript{2}O), 4.34 (d, J = 5.4 Hz, 1H), 3.86 (s, 3H), 3.74-3.63 (m, 2H), 3.31 (bs, CD\textsubscript{3}OD), 2.99-2.90 (m, 1H), 2.58-2.52 (m, 1H), 1.94-1.88 (m, 1H), 1.67-1.60 (m, 2H).

**EXAMPLE 4**

\((\pm)-N\)-hydroxy-1-(4-methoxybenzenesulfonlyl)-2-piperazinecarboxamide hydrochloride

(a) To a solution of \((\pm)-4-benzylxoycarbonyl-2-piperazinecarboxylic acid (1.90 grams, 7.2 mmol) in dioxane-water (10 ml, ca. 1:1) is added 1N sodium hydroxide solution (15 ml, 15 mmol) followed by 4-methoxybenzenesulfonyl chloride. The solution is stirred for 1 hour, acidified with 1N hydrochloric acid and extracted with ethyl acetate. The combined extracts are dried (sodium sulfate), filtered and concentrated. The crude product is purified by silica gel chromatography (elution with 2:1 ethyl acetate-hexanes with 1% acetic acid) to provide \((\pm)-1-(4-methoxybenzenesulfonlyl)-4-benzylxoycarbonyl-2-piperazinecarboxylic acid.

(b) To a solution of \((\pm)-1-(4-methoxybenzenesulfonlyl)-4-benzylxoycarbonyl-2-piperazinecarboxylic acid (100 mg, 0.23 mmol) in methylene chloride (5 ml) is added O-t-butylhydroxylamine hydrochloride (35 mg, 0.28 mmol), dimethylaminopyridine (37 mg, 0.30 mmol), and dicyclohexycarbodiimide (57 mg, 0.28 mmol). After stirring overnight, the reaction is diluted with hexanes and the precipitated solid filtered off. The solution is concentrated and the crude product is purified by silica gel chromatography (elution with 2:1 ethyl acetate-hexanes with 1% acetic acid) to provide \((\pm)-N-(t-butyloxy)-1-(4-methoxybenzenesulfonlyl)-4-benzylxoycarbonyl-2-piperazinecarboxamide.

(c) To a solution of \((\pm)-N-(t-butyloxy)-1-(4-methoxybenzenesulfonlyl)-4-benzylxoycarbonyl-2-piperazinecarboxamide (68 mg, 0.134 mmol), in methanol (6 ml)
is added 10% palladium on carbon (7 mg). The flask is evacuated and backfilled with hydrogen (repeated 2 times). The reaction mixture is then stirred for 1 hour at which time it is filtered through Celite™ and concentrated. The product (±)-N-(t-butyloxy)-1-(4-methoxybenzenesulfonyl)-2-piperazinecarboxamide is used without any further purification.

(d) To a solution of (±)-N-(t-butyloxy)-1-(4-methoxybenzenesulfonyl)-2-piperazinecarboxamide (30 mg, in dichloroethane is added ethanol (1 drop). The solution is cooled to -10°C and hydrogen chloride gase is bubbled through for 5 minutes. The reaction is then sealed and stirred for 24 hours at which time the volume is reduced to 1/3 by evaporation and the precipitated solids are filtered and dried (in vacuo) to give (±)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-2-piperazinecarboxamide hydrochloride as a white solid. Melting point 167 °C. (dec.). Mass spectrum (thermospray): m/z 343 (m + 1 100%). 1H NMR (CD3OD, 250 MHz, ppm): δ 7.76 (d, J = 8.9 Hz, 2H), 7.07 (d, J = 8.9 Hz, 2H), 3.87 (bs, H2O), 4.19 (d, J = 3.3 Hz, 1H), 3.87 (s, 3H), 3.58 (bd, J = 6.2 Hz, 1H), 3.42 (bd, J = 6.1 Hz, 1H), 3.30 (bs, CD3OD), 3.16 (d, J = 13.5 Hz, 1H), 2.87 (bd, J = 13.3 Hz, 1H), 2.69 (dd, J = 13.3, 3.0 Hz, 1H), 2.51 (dt, J = 12.5, 3.8 Hz, 1H).

**EXAMPLE 5**

**N-hydroxy-1-(4-methoxybenzenesulfonyl)-5-oxo-piperazine-2-carboxamide**

(a) To a solution of (±)-benzoxycarbonylamino-2-t-butoxycarbonyl aminopropionate (2.8 grams, 7.9 mmol) in methylene chloride (25 ml) at 0°C is added a solution of hydrochloric acid (g) dissolved in dioxane (25 ml). The solution is stirred at 0°C for 4 hours and then concentrated. The crude product 3-benzoxycarbonylamino-2-amino-propionic acid methyl ester hydrochloride is used without further purification.

(b) 3-benzoxycarbonylamino-2-amino-propionic acid methyl ester hydrochloride is subjected to the conditions described in Example 1a. The crude product is purified by silica gel chromatography (elution with 1:1 hexane-ethyl acetate) to provide (±)-3-benzoxycarbonylamino-2-(4-methoxybenzenesulfonylamino)-propionic acid methyl ester.

(c) (±)-3-benzoxycarbonylamino-2-(4-methoxybenzene sulfonylamino)-propionic acid methyl ester is subjected to the conditions described in Example 1. The crude product is purified by silica gel chromatography (elution with 3:2 ethyl acetate-
hexane) to provide (±)-3-benzyloxy carbonylamino-2-[t-butoxycarbonylmethyl-(4-methoxybenzenesulfonyl)-amino]-propionic acid methyl ester.

(d) (±)-3-benzyloxy carbonylamino-2-[t-butoxycarbonylmethyl-(4-methoxybenzenesulfonyl)-amino]-propionic acid methyl ester is subjected to the conditions described in Example 4c. The product 3-amino-2-[t-butoxycarbonylmethyl-(4-methoxybenzene-sulfonyl)-amino]-propionic acid methyl ester is used without further purification.

(e) To a solution of 3-amino-2-[t-butoxycarbonylmethyl-(4-methoxybenzenesulfonyl)-amino]-propionic acid methyl ester (2.46 grams, 6.1 mmol) in methylene chloride (20 ml) at 0°C is added trifluoroacetic acid (5 ml). The solution is stirred at 0°C for 12 hours and then concentrated. The crude product 3-amino-2-[carboxymethyl-(4-methoxybenzenesulfonyl)-amino]-propionic acid methyl ester trifluoroacetic acid salt is used without further purification.

(f) To a solution of 3-amino-2-[carboxymethyl-(4-methoxybenzenesulfonyl)-amino]-propionic acid methyl ester trifluoroacetic acid salt (2.11 grams, 6.1 mmol) in methylene chloride (5 ml) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.76 grams, 9.2 mmol) and triethylamine (3.4 ml, 24.4 mmol). The resulting mixture is stirred overnight, diluted with ethyl acetate and washed with 1N hydrochloric acid. The organic layer is dried (sodium sulfate), filtered and concentrated. The crude product is purified by silica gel chromatography (elution with ethyl acetate) to provide 1-(4-methoxybenzenesulfonyl)-5-oxo-piperazine-2-carboxylic acid methyl ester.

(g) To a solution of 1-(4-methoxybenzenesulfonyl)-5-oxo-piperazine-2-carboxylic acid methyl ester (200 mg, 0.61 mmol) in methanol-tetrahydrofuran-water (5 ml, ca. 6:2:1) at 0°C is added lithium hydroxide (64 mg, 1.53 mmol). The resulting mixture is stirred for 30 minutes, acidified with 1N hydrochloric acid and extracted with ethyl acetate. The combined extracts are dried (sodium sulfate), filtered and concentrated. The crude product 1-(4-methoxybenzenesulfonyl)-5-oxo-piperazine-2-carboxylic acid is used without further purification.

(h) To a solution of 1-(4-methoxybenzenesulfonyl)-5-oxo-piperazine-2-carboxylic acid (166 mg, 0.53 mmol) in methylene chloride (5 ml) is added 0-benzyl hydroxylamine hydrochloride (255 mg, 1.6 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (153 mg, 0.8 mmol) and triethylamine (370 µL 2.65
mmol). The resulting mixture is stirred overnight, diluted with ethyl acetate and washed with 1N hydrochloric acid. The organic layer is dried (sodium sulfate), filtered and concentrated. The crude product is purified by silica gel chromatography (elution with 5% methanol in methylene chloride) to provide N-(benzyloxy)-1-(4-methoxybenzenesulfonfyl)-5-oxo-piperazine-2-carboxamide.

(i) N-(benzyloxy)-1-(4-methoxybenzenesulfonfyl)-5-oxo-piperazine-2-carboxamide is subjected to the conditions described in Example 4c to give N-hydroxy-1-(4-methoxybenzenesulfonfyl)-5-oxo-piperazine-2-carboxamide as a white solid. Mass spectrum (thermospray): m/z 343 (m+H, 60%), (m+NH4+, 17%). 

\[ \text{H NMR (CD}_3\text{OD), 250 MHz, ppm} \]
\[ \delta 7.79 (d, J = 8.9 \text{ Hz, 2H}), 4.90 (s, H}_2\text{O), 4.47 (dd, J = 5.0, 3.2 Hz, 1H), (4.03, s, 2H), 3.88 (s, 3H), 3.47 (dd, J = 13.4, 3.2 Hz, 1H), 3.35-3.30 (m, 1H), 3.30 (s, CD}_3\text{OD) } \]

**EXAMPLE 6**

**N-hydroxy-1-(4-methoxybenzenesulfonfyl)-morpholin-2-carboxamide**

(a) morpholine-2-carboxylic acid is subjected to the conditions described in Example 4a to give 1-(4-methoxybenzenesulfonfyl)-morpholin-2-carboxylic acid.

(b) 1-(4-methoxybenzenesulfonfyl)-morpholin-2-carboxylic acid is subjected to the conditions described in example 5h to give N-benzyloxy-1-(4-methoxybenzenesulfonfyl)-morpholin-2-carboxamide.

(c) N-benzyloxy-1-(4-methoxybenzenesulfonfyl)-morpholin-2-carboxamide is subjected to the conditions described in Example 4c to give N-hydroxy-1-(4-methoxybenzenesulfonfyl)-morpholin-2-carboxamide as a white foam. Mass spectrum (thermospray): m/z 343 (m+H, 100%), [\( \alpha \)\(_D\)] = +57° (c = 0.60, CHCl₃). 

\[ \text{H NMR (CDCl}_3\text{), 250 MHz, ppm} \]
\[ \delta 7.78 (bd, J = 8.0 \text{ Hz, 2H}), 7.38 (bs, 1H), 7.01 (bd, J = 8.0 \text{ Hz, 2H}), (4.34 (bs, J = 2H), 3.87 (s, 3H), 3.85-3.30 (m, 3H), 3.30-3.15 (m, 2H). \]
1. A compound of the formula

or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond;

X is carbon, oxygen or sulfur;
Y is carbon, oxygen, sulfur, sulfide, sulfone or nitrogen;
R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ and R₉ are selected from the group consisting of hydrogen, (C₁-C₆)alkyl optionally substituted by (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₅-C₁₀)aryl, (C₅-C₆)heteroaryl, (C₅-C₁₀)arylamino, (C₆-C₁₀)arylothio, (C₅-C₁₀)aryloxy, (C₆-C₉)heteroarylamino, (C₆-C₉)heteroarylothio, (C₆-C₉)heteroaryloxy, (C₅-C₁₀)aryl(C₅-C₁₀)arylin, (C₅-C₉)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl,(C₆-C₁₀)aryl(C₁-C₆)alcohol, (C₆-C₉)heteroarylmethyl(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acythio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₁-C₆)sulfinyl, (C₁-C₆)alkylsulfanyl, (C₁-C₆)arylsulfanyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkylamino)₂, (C₂-C₆)alkenyl, (C₆-C₁₀)aryl(C₂-C₆)alkenyl, (C₆-C₉)heteroarylmethyl(C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₆-C₁₀)aryl(C₂-C₆)alkynyl, (C₆-C₉)heteroarylmethyl(C₂-C₆)alkynyl, (C₂-C₆)alkylamino, (C₂-C₆)alkylthio, (C₂-C₆)alkoxy, trifluoromethyl, (C₂-C₆)alkyl

(difluoromethylene), (C₁-C₆)alkyl(difluoromethylene)(C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₆-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₆)arylothio, (C₆-C₁₀)aryloxy, (C₆-C₉)heteroarylamino, (C₆-C₉)heteroarylothio, (C₆-C₉)heteroaryloxy, (C₂-C₆)cycloalkyl, (C₁-C₆)alkyl(hydroxymethylene), piperidyl, (C₁-C₆)alkylpiperidyl, (C₂-C₆)acylamino, (C₁-C₆)alkyl...
C₆acythio, (C₁-C₉)acyloxy, R¹³(C₁-C₉)alkyl wherein R¹³ is (C₁-C₉)acylpiperazino, (C₆-C₁₀)aryl(piperazino, (C₅-C₉)heteroaryl(piperazino, (C₁-C₉)alkyl)piperazino, (C₆-C₉)aryl(piperazino, (C₅-C₉)heteroaryl(C₁-C₉)alkyl)piperazino, morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl, (C₁-C₉)alkyl(piperidyl, (C₅-C₁₀)aryl(piperidyl, (C₅-C₉)heteroaryl(piperidyl(C₁-C₉)alkyl, (C₅-C₉)heteroaryl(piperidyl(C₁-C₉)alkyl or (C₁-C₉)acylpiperidyl; or a group of the formula

\[
\begin{array}{c}
\text{O} \\
\text{Z} \\
\text{CH}_2 \_n \\
\end{array}
\]

wherein n is 0 to 6;

Z is hydroxy, (C₁-C₉)alkoxy or NR¹⁴R¹⁵ wherein R¹⁴ and R¹⁵ are each independently selected from the group consisting of hydrogen, (C₁-C₉)alkyl optionally substituted by (C₁-C₉)alkyl(piperidyl, (C₅-C₁₀)aryl(piperidyl, (C₅-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₅-C₁₀)aryl or (C₅-C₉)cycloalkyl; piperidyl, (C₁-C₉)alkylpiperidyl, (C₆-C₁₀)aryl(piperidyl, (C₅-C₉)heteroaryl(piperidyl, (C₁-C₉)acylpiperidyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)aryl(C₃-C₉)cycloalkyl, R¹⁶(C₂-C₉)alkyl, (C₁-C₉)alkyl(CHR¹⁸)(C₁-C₉)alkyl wherein R¹⁸ is hydroxy, (C₁-C₉)alkoxy, (C₁-C₉)alkoxy, piperazino, (C₅-C₉)acrylamino, (C₁-C₉)alkylthio, (C₆-C₁₀)arylthio, (C₁-C₉)alkylsulfanyl, (C₅-C₁₀)aryl(sulfanyl, (C₅-C₉)alkylsulfanyl, (C₅-C₁₀)aryl(sulfanyl, [(C₁-C₉)alkyl]₆ amin, (C₁-C₉)alkyl(piperazino, (C₁-C₉)acylpiperazino, (C₆-C₁₀)aryl(C₁-C₉)alkylpiperazino, (C₅-C₉)heteroaryl(C₁-C₉)alkylpiperazino, morpholino, thiomorpholino, piperidino or pyrrolidino; R¹⁷(C₁-C₉)alkyl, (C₁-C₉)alkyl(CHR¹⁹)(C₁-C₉)alkyl wherein R¹⁹ is piperidyl or (C₁-C₉)alkylpiperidyl; and CH(R¹⁸)COR¹⁹ wherein R¹⁸ is hydroxy, (C₁-C₉)alkyl, (C₆-C₁₀)aryl(C₁-C₉)alkyl, (C₆-C₉)heteroaryl(C₁-C₉)alkyl, (C₁-C₉)alkylthio(C₁-C₉)alkyl, (C₆-C₁₀)arylthio(C₁-C₉)alkyl, (C₁-C₉)alkylsulfanyl(C₁-C₉)alkyl, (C₁-C₉)alkylsulfanyl(C₁-C₉)alkyl, (C₁-C₉)alkylsulfanyl(C₁-C₉)alkyl, (C₁-C₉)alkyl(sulfanyl, (C₁-C₉)alkyl, hydroxy(C₁-C₉)alkyl, amino(C₁-C₉)alkyl, (C₁-C₉)alkylamino(C₁-C₉)alkyl, [(C₁-C₉)alkylamino]₂(C₁-C₉)alkyl, R²₀R²¹NCO(C₁-C₉)alkyl or R²₀OOC(C₁-C₉)alkyl wherein R²₀ and R²¹ are each independently selected from the group consisting of hydrogen, (C₁-
C\textsubscript{2}alkyl, (C\textsubscript{6}-C\textsubscript{10})aryl(C\textsubscript{1}-C\textsubscript{6})alkyl and (C\textsubscript{6}-C\textsubscript{10})heteroaryl(C\textsubscript{1}-C\textsubscript{6})alkyl; and R\textsuperscript{19} is R\textsuperscript{22}O or R\textsuperscript{22}R\textsuperscript{23}N wherein R\textsuperscript{22} and R\textsuperscript{23} are each independently selected from the group consisting of hydrogen, (C\textsubscript{1}-C\textsubscript{6})alkyl, (C\textsubscript{6}-C\textsubscript{10})aryl(C\textsubscript{1}-C\textsubscript{6})alkyl and (C\textsubscript{6}-C\textsubscript{10})heteroaryl(C\textsubscript{1}-C\textsubscript{6})alkyl; or R\textsuperscript{14} and R\textsuperscript{15}, or R\textsuperscript{20} and R\textsuperscript{21}, or R\textsuperscript{22} and R\textsuperscript{23} may be taken together to form an azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, (C\textsubscript{1}-C\textsubscript{6})acylpiperazinyl, (C\textsubscript{1}-C\textsubscript{6})alkylpiperazinyl, (C\textsubscript{6}-C\textsubscript{10})arylpiperazinyl, (C\textsubscript{6}-C\textsubscript{10})heteroarylpiperazinyl or a bridged diazabicycloalkyl ring selected from the group consisting of

\begin{align*}
\text{a} & \quad \text{b} & \quad \text{c} \\
\text{d} & \quad \text{e}
\end{align*}

wherein r is 1, 2 or 3;
m is 1 or 2;
p is 0 or 1; and
Q is hydrogen, (C\textsubscript{1}-C\textsubscript{3})alkyl, (C\textsubscript{1}-C\textsubscript{6})acyl or (C\textsubscript{1}-C\textsubscript{6})alkoxy carbamoyl;
or R¹ and R², or R³ and R⁴, or R⁵ and R⁶ may be taken together to form a carbonyl;

or R¹ and R², or R³ and R⁴, or R⁵ and R⁶, or R⁷ and R⁸ may be taken together to form a (C₃-C₅)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula

```
\[ \text{N} \quad \text{R}^{24} \]
```

wherein R²⁴ is hydrogen, (C₁-C₆)acyl, (C₁-C₆)alkyl, (C₅-C₁₀)aryl(C₁-C₆)alkyl, (C₂-C₆)heteroaryl(C₁-C₆)alkyl or (C₂-C₆)alkylsulfonyl; and

Ar is (C₅-C₁₀)aryl or (C₂-C₆)heteroaryl, each of which may be optionally substituted by (C₁-C₆)alkyl, one or two (C₁-C₆)alkoxy, (C₅-C₁₀)aryloxy or (C₂-C₆)heteroaryloxy;

with the proviso that R⁷ is other than hydrogen only when R⁸ is other than hydrogen;

with the proviso that R⁸ is other than hydrogen only when R⁶ is other than hydrogen;

with the proviso that R³ is other than hydrogen only when R⁴ is other than hydrogen;

with the proviso that R² is other than hydrogen only when R¹ is other than hydrogen;

with the proviso that when R¹, R² and R³ are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions;

with the proviso that when X is nitrogen, R⁴ is not present;

with the proviso that when X is oxygen, sulfur, sulfoxide, sulfone or nitrogen and when one or more of the group consisting of R¹, R², R⁵ and R⁶, is a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 4- or 6- positions;

with the proviso that when Y is oxygen, sulfur, sulfoxide, sulfone or nitrogen and when one or more of the group consisting of R³, R⁴, R⁷ and R⁸, are independently a
substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 3- or 5- positions;

with the proviso that when X is oxygen, sulfur, sulfoxide or sulfone, R³ and R⁴ are not present;

with the proviso that when Y is nitrogen, R⁴ is not present;

with the proviso that when Y is oxygen, sulfur, sulfoxide or sulfone, R⁵ and R⁶ are not present;

with the proviso that when Y is nitrogen, R⁶ is not present;

with the proviso that when the broken line represents a double bond, R⁴ and R⁶ are not present;

with the proviso that when R³ and R⁵ are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y;

with the proviso that when either the X or Y position is oxygen, sulfur, sulfoxide, sulfone or nitrogen, the other of X or Y is carbon;

with the proviso that when X or Y is defined by a heteroatom, the broken line does not represent a double bond;

with the proviso that when R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are all defined by hydrogen or (C₁-C₆)alkyl, either X or Y is oxygen, sulfur, sulfoxide, sulfone or nitrogen, or the broken line represents a double bond.

2. A compound according to claim 1, wherein Y is oxygen, nitrogen or sulfur.

3. A compound according to claim 1, wherein Ar is 4-methoxyphenyl or 4-phenoxyphenyl.

4. A compound according to claim 1, wherein R⁷ is (C₆-C₁₀)aryl, (C₆-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₆-C₉)heteroaryl(C₁-C₆)alkyl, carboxylic acid or carboxylic acid (C₁-C₆)alkyl.

5. A compound according to claim 1, wherein R², R³, R⁸, R⁷ and R⁹ are hydrogen.

6. A compound according to claim 1, wherein Y is carbon, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R⁸ is (C₆-C₁₀)arylalkynyl or (C₆-C₉)heteroarylalkynyl.
7. A compound according to claim 1, wherein Y is oxygen, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is (C₅-C₁₀)arylalkynyl or (C₅-C₈)heteroarylalkynyl.

8. A compound according to claim 1, wherein Y is carbon, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is carboxylic acid or carboxylic acid (C₁-C₅)alkyl.

9. A compound according to claim 1, wherein Y is oxygen, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is carboxylic acid or carboxylic acid (C₁-C₅)alkyl.

10. A compound according to claim 1, wherein Y is carbon, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is (C₅-C₁₀)arylalkynyl or (C₅-C₈)heteroarylalkynyl.

11. A compound according to claim 1, wherein Y is oxygen, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is (C₅-C₁₀)arylalkynyl or (C₅-C₈)heteroarylalkynyl.

12. A compound according to claim 1, wherein Y is carbon, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is carboxylic acid or carboxylic acid (C₁-C₅)alkyl.

13. A compound according to claim 1, wherein Y is oxygen, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is carboxylic acid or carboxylic acid (C₁-C₅)alkyl.

14. A compound according to claim 1, wherein Y is carbon, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is (C₁-C₅)alkylamino.

15. A compound according to claim 1, wherein Y is oxygen, Ar is 4-methoxyphenyl or 4-phenoxyphenyl and R² is (C₁-C₅)alkylamino.

16. A compound according to claim 1, wherein said compound is selected from the group consisting of:

- (2R,3S)-N-hydroxy-3-ethynyl-1-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide;
- (2R,3S)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(5-methoxythiophene-2-yl-ethynyl)-piperidine-2-carboxamide;
- (2R,3R)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(3-pyridin-3-yl-prop-2-ynyl)-piperidine-2-carboxamide;
(2S,3R)-N-hydroxy-4-(4-methoxybenzenesulfonyl)-2-pyridine-3-yl-morpholine-3-carboxamide;
(2S,3R)-N-hydroxy-2-hydroxycarbamoyl-4-(4-methoxybenzenesulfonyl)-morpholine-3-carboxamide;
(2R,3R)-N-hydroxy-2-hydroxycarbamoyl-4-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide;
(2R,3S)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-3-(4-phenylpyridine-2-yl)-piperidine-2-carboxamide;
(2S,3R)-N-hydroxy-1-(4-methoxybenzenesulfonyl)-2-(4-phenylpyridine-2-yl)-morpholine-2-carboxamide;
(2R,3S)-N-hydroxy-3-(2-chloro-4-fluorophenyl)-1-(4-methoxybenzenesulfonyl)-piperidine-2-carboxamide; and
(2S,3R)-N-hydroxy-2-(2-chloro-4-fluorophenyl)-1-(4-methoxybenzenesulfonyl)-piperidine-3-carboxamide.

17. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such treatments or inhibition and a pharmaceutically acceptable carrier.

18. A method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

19. A method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to
said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in treating such a condition.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D211/96 A61K31/445 C07D241/04 C07D241/08

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>EP,A,0 606 046 (CIBA GEIGY AG) 13 July 1994 see claims 1,2; example 6</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Date of the actual completion of the international search

12 December 1995

Date of mailing of the international search report

20.12.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HU Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

De Jong, B
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. □ Claims Nos.:  
   because they relate to subject matter not required to be searched by this Authority, namely:  
   Although claims 18 and 19 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Nos.:  
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. □ Claims Nos.:  
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest
□ The additional search fees were accompanied by the applicant's protest.
□ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AU-B- 5265593</td>
<td>04-05-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 2112779</td>
<td>07-07-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI-A- 940012</td>
<td>07-07-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU-A- 70536</td>
<td>30-10-95</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO-A- 940038</td>
<td>07-07-94</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ-A- 250517</td>
<td>26-10-95</td>
</tr>
</tbody>
</table>